title: [Risk factors associated with the development of motor complications in Parkinson's disease. A study in a Chilean population].
abstract: BACKGROUND
  The treatment of Parkinson's disease (PD) is based on the use of levodopa and/or dopaminergic agonists. This treatment is associated with motor complications in around 50% of the patients over 5 years of treatment. Numerous risk factors have been related to the onset of this motor complications.
  
  
  OBJECTIVE
  To describe the prevalence and risk factors associated with the occurrence of motor complications in our population.
  
  
  METHODS
  PD patients in control in a movement disorders center were consecutively recruited. Using a multivariate logistic regression model the risk factors associated with the onset of MC were determined.
  
  
  RESULTS
  124 patients were evaluated. Mean age was 66,2 +/- 10,1 years, the years of PD evolution were 8,1 +/- 5,2 years, the on UPDRS score was 27,7 +/- 14,8 points. A 62% of the patients presented at least one motor complication, a 52% with wearing off and a 47,2% dyskinesias. Both motor complications were present in 39%. The multivariate analysis showed that that female sex and the dose of levodopa equivalents were the risk factors for the occurrence of dyskinesias. For the wearing off the main risk factor were the years of evolution of the PD.
  
  
  CONCLUSIONS
  This study shows that the time of evolution of the PD is the main risk factor for the wearing off and the female sex and the dose of levodopa equivalents are the risk factor for the development of dyskinesias. These results are in agreement with the previously reported in the literature for other populations.
authors.affiliation: Departamento de Neurología, Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile.
authors.forename: C
authors.initials: C
authors.lastname: Juri-Claveria
authors.forename: C
authors.initials: C
authors.lastname: Aguirre-M
authors.forename: P
authors.initials: P
authors.lastname: Viviani-G
authors.forename: P
authors.initials: P
authors.lastname: Chana-Cuevas
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects; D002677:Chile; D018450:Disease Progression; D018491:Dopamine Agonists / Q000009:adverse effects; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008875:Middle Aged; D009069:Movement Disorders / Q000209:etiology* / Q000503:physiopathology; D015999:Multivariate Analysis; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012307:Risk Factors
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa